Cargando…
Oridonin Inhibits SARS‐CoV‐2 by Targeting Its 3C‐Like Protease
The current COVID‐19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is an enormous threat to public health. The SARS‐CoV‐2 3C‐like protease (3CLpro), which is critical for viral replication and transcription, has been recognized as an ideal drug target. Herein, it...
Autores principales: | Zhong, Baisen, Peng, Weiyu, Du, Shan, Chen, Bingyi, Feng, Yajuan, Hu, Xinfeng, Lai, Qi, Liu, Shujie, Zhou, Zhong-Wei, Fang, Pengfei, Wu, Yan, Gao, Feng, Zhou, Huihao, Sun, Litao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111243/ https://www.ncbi.nlm.nih.gov/pubmed/35600064 http://dx.doi.org/10.1002/smsc.202100124 |
Ejemplares similares
-
Oridonin Inhibits SARS‐CoV‐2 by Targeting Its 3C‐Like Protease
por: Zhong, Baisen, et al.
Publicado: (2022) -
Oridonin inhibits SARS-CoV-2 replication by targeting viral proteinase and polymerase
por: Zhang, Zherui, et al.
Publicado: (2023) -
Antiangiogenic effects of oridonin
por: Tian, Lili, et al.
Publicado: (2017) -
Design and synthesis of novel oridonin analogues as potent anticancer agents
por: Shen, Qing-Kun, et al.
Publicado: (2018) -
Oridonin suppresses autophagy and survival in rheumatoid arthritis fibroblast-like synoviocytes
por: He, Shou-Di, et al.
Publicado: (2020)